Holen Sie sich die Stockscreener-App
52.40
1.76%
-0.94
Handel nachbörslich:
51.87
-0.53
-1.01%
Schlusskurs vom Vortag:
$53.34
Offen:
$54
24-Stunden-Volumen:
15.77M
Relative Volume:
0.45
Marktkapitalisierung:
$11.29B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
75.94
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
-2.09%
1M Leistung:
+49.54%
6M Leistung:
+62.63%
1J Leistung:
+167.62%
1-Tages-Spanne:
$52.11
$55.00
1-Wochen-Bereich:
$51.41
$56.30
52-Wochen-Spanne:
$13.47
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Vergleichen Sie HIMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
52.40 | 11.98B | 1.78B | 164.40M | 236.51M | 0.69 |
|
PG
Procter Gamble Co
|
168.56 | 386.92B | 83.93B | 15.50B | 15.03B | 6.30 |
|
UL
Unilever Plc Adr
|
63.57 | 155.28B | 65.10B | 6.16B | 0 | 2.4569 |
|
CL
Colgate Palmolive Co
|
92.30 | 73.67B | 19.95B | 2.90B | 3.47B | 3.54 |
|
KMB
Kimberly Clark Corp
|
143.84 | 46.37B | 19.75B | 2.47B | 2.39B | 7.34 |
|
KVUE
Kenvue Inc
|
23.58 | 45.12B | 15.30B | 1.06B | 1.45B | 0.55 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Insider Sell: Soleil Boughton Sells Shares of Hims & Hers Health Inc (HIMS) - GuruFocus
Hims & Hers Health Stock: After Doubling, It May Be Too Late To Buy (NYSE:HIMS) - Seeking Alpha
HIMS: AI Advancements Set to Boost Direct-to-Consumer Value | HIMS Stock News - GuruFocus
Hims & Hers Stock Falls Despite the Latest Wegovy Availability Offer - MSN
Is HIMS stock about to get 'Squid Game' treatment? - Investorsobserver
Why Hims & Hers Health Inc. (HIMS) Went Down On Tuesday - Insider Monkey
10 Stocks Got Wiped Out. Are You Holding Any? - Insider Monkey
SA analyst downgrades: NVDA, OKTA, HIMS, DDOG, WDAY, RNG - Seeking Alpha
3 Surprising Stocks That Have More Than Doubled in 2025 - AOL.com
3 Surprising Stocks That Have More Than Doubled in 2025 - The Motley Fool
Hims & Hers Health (HIMS) – Research Analysts’ Weekly Ratings Updates - Defense World
Medical Stocks To Watch Now – May 24th - Defense World
Hims & Hers Health (NYSE:HIMS) Trading Up 2.8% – Here’s What Happened - Defense World
Super Micro Computer, Hims & Hers And Aurora Innovation Are Among Top 10 Large-Cap Losers Last Week (May 19-May 23): Are The Others In Your Portfolio? - Benzinga
Hims & Hers Health: New Guidance Creates Huge Risk For Shorts (NYSE:HIMS) - Seeking Alpha
Why Hims & Hers Health Stock (HIMS) Is Too Hot to Handle - Yahoo Finance
‘Time to Choose Sides on HIMS Stock’ as Analysts Assign Mixed Ratings - The Globe and Mail
Mixed options sentiment in Hims and Hers Health with shares up 2.0% - TipRanks
HIMS Stock Sees Moderate Options Activity with Increased Downside Demand | HIMS Stock News - GuruFocus
Hims & Hers: Not The Dip I Want To Buy (Rating Downgrade) (NYSE:HIMS) - Seeking Alpha
Hims & Hers appoints Farshad Shadloo as VP of communications - Medical Marketing and Media
Hims & Hers Health and AST SpaceMobile have been highlighted as Zacks Bull and Bear of the Day - Yahoo Finance
Validea Detailed Fundamental AnalysisHIMS - Nasdaq
When the Price of (HIMS) Talks, People Listen - news.stocktradersdaily.com
Hims Online Psychiatry 2025 Review - Everyday Health
Why Hims & Hers Health (HIMS) Stock Is Falling Today - Yahoo
Hims & Hers Introduces 6-Month Wegovy New Customer Offer - marketscreener.com
HIMS Launches Affordable Wegovy Access for Eligible Customers | - GuruFocus
Hims & Hers offers Wegovy at new accessible price By Investing.com - Investing.com India
HIMS Launches Affordable Wegovy Access for Eligible Customers | HIMS Stock News - GuruFocus
U.S. Markets Finished Mixed Thursday As Snowflake Led, Hims & Hers Health Lagged - Barron's
Hims & Hers offers Wegovy at new accessible price - Investing.com
Citi maintains Sell on Hims & Hers, holds $30 price target - Investing.com
Hims & Hers Introduces 6-Month Wegovy® New Customer Offer - galvnews.com
Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off? - MarketBeat
Hims & Hers Health Inc (HIMS) Stock Price Down 4.07% on May 22 - GuruFocus
Cigna’s $200 Weight-Loss Drug Cap Shakes Up Hims & Hers Stock - Wall Street Pit
Citi maintains sell rating on Hims & Hers with $30 target - Investing.com India
Hims & Hers Stock Drops After Evernorth Announces Cheaper Pricing For Weight-Loss Drugs: Retail’s Dull - MSN
Snowflake stock gains, Nvidia & Navitas, Hims & Hers slips - Yahoo Finance
HIMS Stock Declines by Over 10% Marking Significant Drop | HIMS - GuruFocus
Hims & Hers Health Stock Is Tumbling Thursday: What's Happening?Hims & Hers Health (NYSE:HIMS) - Benzinga
HIMS Stock Declines by Over 10% Marking Significant Drop | HIMS Stock News - GuruFocus
HIMS Stock Experiences Notable Decline | HIMS Stock News - GuruFocus
HIMS Shares Decline Following Evernorth Weight Loss Plan Announcement | HIMS Stock News - GuruFocus
Cigna to offer $200 Wegovy, Zepbound weight-loss benefit - Reuters
Up 157% in 2025, Is It Too Late to Buy Hims & Hers Stock? - AOL.com
Truist maintains Hims & Hers stock hold rating, $45 target By Investing.com - Investing.com Nigeria
Morgan Stanley maintains Hims & Hers stock with $40 target By Investing.com - Investing.com Nigeria
Morgan Stanley maintains Hims & Hers stock with $40 target - Investing.com
Hims & Hers Health: Stabilizing Growth and Cautious Revenue Guidance Lead to Hold Rating - TipRanks
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):